2020
Dissecting the immunosuppressive tumor microenvironments in Glioblastoma-on-a-Chip for optimized PD-1 immunotherapy
Cui X, Ma C, Vasudevaraja V, Serrano J, Tong J, Peng Y, Delorenzo M, Shen G, Frenster J, Morales R, Qian W, Tsirigos A, Chi A, Jain R, Kurz S, Sulman E, Placantonakis D, Snuderl M, Chen W. Dissecting the immunosuppressive tumor microenvironments in Glioblastoma-on-a-Chip for optimized PD-1 immunotherapy. ELife 2020, 9: e52253. PMID: 32909947, PMCID: PMC7556869, DOI: 10.7554/elife.52253.Peer-Reviewed Original ResearchMeSH KeywordsGlioblastomaImmunotherapyLab-On-A-Chip DevicesProgrammed Cell Death 1 ReceptorTumor MicroenvironmentConceptsProgrammed cell death protein 1Immunosuppressive tumor microenvironmentTumor-associated macrophagesTumor microenvironmentCD163+ tumor-associated macrophagesPD-1/PD-L1 immune checkpointCSF-1R inhibitor BLZ945Molecularly distinct GBM subtypesCell death protein 1Anti-PD-1 immunotherapyT cell functionNivolumab efficacyImmunotherapy efficacyImmune checkpointsImmune signaturesImmunosuppressive mechanismsT cellsM2-TAMsCo-administeredGlioblastoma patientsIL-10CSF-1RCSF-1ImmunotherapyProneural glioblastoma
2018
PD-1 inhibition has only limited clinical benefit in patients with recurrent high-grade glioma.
Kurz S, Cabrera L, Hastie D, Huang R, Unadkat P, Rinne M, Nayak L, Lee E, Reardon D, Wen P. PD-1 inhibition has only limited clinical benefit in patients with recurrent high-grade glioma. Neurology 2018, 91: e1355-e1359. PMID: 30171077, DOI: 10.1212/wnl.0000000000006283.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedAntineoplastic AgentsBevacizumabBrain NeoplasmsFemaleGliomaHumansMaleMiddle AgedNeoplasm Recurrence, LocalNivolumabProgrammed Cell Death 1 ReceptorRetrospective StudiesSalvage TherapySurvival AnalysisTreatment OutcomeYoung AdultConceptsRecurrent high-grade gliomaHigh-grade gliomasRetrospective observational studySalvage therapySurvival benefitSingle-institution retrospective observational studyPD-1 blocking antibodiesObservational studyPD-1 inhibitionProgression-free survivalClass IV evidenceConcurrent bevacizumabAntibody nivolumabPD-1Median survivalClinical benefitImproved survivalNivolumabPembrolizumabAdult patientsBevacizumabIV evidenceClinical trialsPatient populationPatients